Tirzepatide benefits

Eli Lilly's dual GIP/GLP-1 receptor agonist tirzepatide has already demonstrated its benefits in patients with diabetes, obesity, sleep apnea and fatty liver disease. Now, Lilly is eying another major market with positive results from a trial in patients with heart failure (HF).

In the phase 3 SUMMIT trial, Lilly's tirzepatide reduced the risk of adverse HF outcomes—such as hospitalization or cardiovascular death—by 38% compared with placebo. The study enrolled 731 patients with HF with preserved ejection fraction (HFpEF) and obesity.